{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T15:31:04Z","timestamp":1772811064700,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2006,2]]},"DOI":"10.1016\/j.urology.2005.08.048","type":"journal-article","created":{"date-parts":[[2006,1,27]],"date-time":"2006-01-27T10:34:01Z","timestamp":1138358041000},"page":"343-348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["More favorable tumor features and progression-free survival rates in a longitudinal prostate cancer screening study: PSA era and threshold-specific effects"],"prefix":"10.1016","volume":"67","author":[{"given":"Thomas L.","family":"Jang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misop","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly A.","family":"Roehl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheila A.","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J.","family":"Catalona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2005.08.048_bib1","first-page":"3","article-title":"Population-based prostate cancer trends in the PSA era","volume":"19","author":"Stephenson","year":"1998","journal-title":"Monogr Urol"},{"key":"10.1016\/j.urology.2005.08.048_bib2","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0090-4295(98)00242-8","article-title":"National trends in the epidemiology of prostate cancer, 1973 to 1994","volume":"52","author":"Farkas","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.urology.2005.08.048_bib3","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0022-5347(01)64231-9","article-title":"Temporal trends in rates of prostate cancer","volume":"158","author":"Newcomer","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2005.08.048_bib4","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/jnci\/91.12.1017","article-title":"Cancer surveillance series: interpreting trends in prostate cancer. Part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates","volume":"91","author":"Hankey","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urology.2005.08.048_bib5","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1056\/NEJM199104253241702","article-title":"Measurement of prostate-specific antigen in serum as a screening test for prostate cancer","volume":"324","author":"Catalona","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2005.08.048_bib6","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1001\/jama.1993.03510080052031","article-title":"Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening","volume":"270","author":"Catalona","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.urology.2005.08.048_bib7","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0090-4295(99)00602-0","article-title":"Lowering PSA cutoffs to enhance detection of curable prostate cancer","volume":"55","author":"Catalona","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.urology.2005.08.048_bib8","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0090-4295(02)01875-7","article-title":"Prostate-specific antigen cutoff of 2.6 ng\/mL for prostate cancer screening is associated with favorable pathologic tumor features","volume":"60","author":"Krumholtz","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.urology.2005.08.048_bib9","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S0022-5347(05)67809-3","article-title":"Prostate cancer detection at low values of prostate specific antigen (PSA)","volume":"163","author":"Schroder","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2005.08.048_bib10","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0025-6196(11)63720-8","article-title":"Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice","volume":"73","author":"Amling","year":"1998","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.urology.2005.08.048_bib11","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0022-5347(01)62251-1","article-title":"The combination of preoperative prostate specific antigen and postoperative pathological findings to predict prostate specific antigen outcome in clinically localized prostate cancer","volume":"160","author":"D\u2019Amico","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2005.08.048_bib12","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/0090-4295(94)90144-9","article-title":"Radical prostatectomy for adenocarcinoma of the prostate","volume":"43","author":"Zietman","year":"1994","journal-title":"Urology"},{"key":"10.1016\/j.urology.2005.08.048_bib13","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S0022-5347(05)65955-1","article-title":"Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer","volume":"166","author":"Han","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2005.08.048_bib14","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0090-4295(02)01814-9","article-title":"Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era","volume":"60","author":"Ung","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.urology.2005.08.048_bib15","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0022-5347(17)32397-2","article-title":"5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer","volume":"152","author":"Catalona","year":"1994","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2005.08.048_bib16","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1016\/S0022-5347(01)62204-3","article-title":"Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer","volume":"160","author":"Catalona","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2005.08.048_bib17","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1001\/jama.1997.03540420048028","article-title":"Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng\/mL and benign prostate examination","volume":"277","author":"Catalona","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.urology.2005.08.048_bib18","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S0022-5347(17)32372-8","article-title":"The nature of prostate cancer detected through prostate specific antigen based screening","volume":"152","author":"Smith","year":"1994","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2005.08.048_bib19","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0094-0143(21)00917-4","article-title":"Using PSA to screen for prostate cancer","volume":"20","author":"Andriole","year":"1993","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.urology.2005.08.048_bib20","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0022-5347(05)68578-3","article-title":"Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies","volume":"162","author":"Catalona","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2005.08.048_bib21","series-title":"Manual for Staging of Cancer","author":"Beahrs","year":"1992"},{"key":"10.1016\/j.urology.2005.08.048_bib22","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0022-5347(17)59889-4","article-title":"Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging","volume":"111","author":"Gleason","year":"1974","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2005.08.048_bib23","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1001\/jama.1997.03540420052029","article-title":"Recommended PSA testing intervals for the detection of curable prostate cancer","volume":"277","author":"Carter","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.urology.2005.08.048_bib24","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0094-0143(02)00002-2","article-title":"Prostate cancer trends in the era of prostate-specific antigen","volume":"29","author":"Stephenson","year":"2002","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.urology.2005.08.048_bib25","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/jama.1995.03520280035036","article-title":"A prospective evaluation of plasma prostate-specific antigen for detection of prostate cancer","volume":"273","author":"Gann","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.urology.2005.08.048_bib26","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1001\/jama.283.22.2975","article-title":"Are increasing 5-year survival rates evidence of success against cancer?","volume":"283","author":"Welch","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.urology.2005.08.048_bib27","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1016\/S0022-5347(01)62202-X","article-title":"Anatomic radical prostatectomy","volume":"160","author":"Walsh","year":"1998","journal-title":"J Urol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429505012070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429505012070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T01:42:44Z","timestamp":1758764564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429505012070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,2]]}},"alternative-id":["S0090429505012070"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2005.08.048","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2006,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"More favorable tumor features and progression-free survival rates in a longitudinal prostate cancer screening study: PSA era and threshold-specific effects","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2005.08.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}